Loading

Please wait...

Tanzeum

Generic Name: albiglutide (AL bi GLOO tide)
Brand Names: Tanzeum
Tanzeum (albiglutide) is used to treat Type 2 Diabetes. Includes Tanzeum side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Tanzeum

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Tanzeum (albiglutide) is an injectable diabetes medicine that helps control blood sugar levels. Tanzeum is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Tanzeum is usually given after other diabetes medications have been tried without success. It is not for treating type 1 diabetes. You should not use Tanzeum if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis. Learn more

Tanzeum Side Effects

Tanzeum Side Effects

Note: This document contains side effect information about albiglutide. Some of the dosage forms listed on this page may not apply to the brand name Tanzeum.

In Summary

Common side effects of Tanzeum include: injection site reaction, diarrhea, and nausea. Other side effects include: vomiting. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to albiglutide: subcutaneous powder for solution

Warning

Subcutaneous route (Powder for Solution)

Carcinogenicity of albiglutide could not be assessed in rodents, but other glucagon-like peptide-1 (GLP-1) receptor agonists have caused thyroid C-cell tumors in rodents at clinically relevant exposures. Human relevance of GLP-1 receptor agonist induced C-cell tumors in rodents has not been determined. It is unknown whether albiglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Albiglutide is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients about the potential risk of MTC with the use of albiglutide and inform them of the symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early detection of MTC.

Along with its needed effects, albiglutide (the active ingredient contained in Tanzeum) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking albiglutide:

Rare

  • Bloating
  • chills or fever
  • darkened urine
  • fast heartbeat
  • loss of appetite
  • nausea, vomiting, or indigestion
  • pains in the stomach, side, or abdomen, possibly radiating to the back

Incidence not known

  • Anxiety, irritability, or mood changes
  • blurred vision
  • cold sweats
  • confusion
  • difficulty with breathing or swallowing
  • dizziness
  • headache
  • increased hunger
  • shakiness
  • skin itching, rash, or redness
  • slurred speech
  • swelling of the face, throat, or tongue
  • unusual tiredness or weakness

Some side effects of albiglutide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Body aches or pain
  • cough
  • diarrhea
  • ear congestion
  • loss of voice
  • muscle pain or stiffness
  • pain in the joints
  • pain or tenderness around the eyes and cheekbones
  • skin reactions, warmth, or redness at the injection site
  • sneezing
  • stuffy or runny nose

For Healthcare Professionals

Applies to albiglutide: subcutaneous powder for injection

General

The most commonly reported adverse reactions have included diarrhea, nausea, and injection site reactions which have included rash, erythema, or itching at the injection site.

Gastrointestinal

The incidence of pancreatitis (adjudicated as likely to be related to therapy) in clinical trials was 0.3% compared with 0% for placebo and 0.1% for comparators (e.g., liraglutide, pioglitazone, glimepiride, sitagliptin, and insulin glargine) with or without background antidiabetic therapy (e.g. metformin)

Gastrointestinal events occurred more frequently with this drug than comparators (38% versus 32%). Diarrhea (13% vs 9%), nausea (12% vs 11%), vomiting (5% vs 4%), and constipation (5% vs 4%) were the most commonly reported, and the majority of events occurred within the first 6 months.

Very common (10% or more): Diarrhea (13.1%), nausea (11.1%),

Common (1% to 10%): Vomiting, gastroesophageal reflux disease, dyspepsia, constipation

Uncommon (0.1% to 1%): Appendicitis, acute pancreatitis, intestinal obstruction

Hypersensitivity

Frequency not reported: Pruritus, rash, dyspnea

Postmarketing reports: Angioedema

Oncologic

Medullary thyroid cancer (MTC) was diagnosed in 1 patient receiving this drug and 1 patient receiving placebo across 8 phase 3 clinical trials; both of these patients had markedly elevated serum calcitonin levels at baseline. MTC has been reported in patients treated with liraglutide, another GLP-1 receptor agonist. The data is insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor use in humans.

Very rare (less than 0.01%): Medullary thyroid cancer

Local

Very common (10% or more): Injection site reaction (up to 15%)

Common (1% to 10%): Injection site hematoma, erythema, rash, and/or pruritus

Uncommon (0.1% to 1%): Injection site hypersensitivity and/or hemorrhage

Metabolic

Very common (10% or more): Hypoglycemia (when used in combination with insulin or sulfonylurea)

Common (1% to 10%): Hypoglycemia (when used as monotherapy in combination with metformin or pioglitazone)

Frequency not reported: Decreased appetite

Renal

Acute renal failure has been reported and may have been the result of dehydration. Postmarketing reports of acute renal failure and worsening chronic renal failure, sometimes requiring hemodialysis, have been reported. Some of these reports have been in patients without known kidney disease. A majority of patients had experienced nausea, vomiting, diarrhea, or dehydration.

Frequency not reported: Acute renal failure

Postmarketing reports: Acute renal failure, worsening of chronic renal failure, sometimes requiring hemodialysis

Musculoskeletal

Very common (10% or more): Back pain (6.7%), arthralgia (6.6%)

Other

Very common (10% or more): Influenza (5.2%)

Respiratory

Very common (10% or more): Upper respiratory tract infection (14.2%), cough (6.9%), sinusitis (6.2%)

Common (1% to 10%): Pneumonia

Cardiovascular

Common (1% to 10%): Atrial fibrillation

Uncommon (0.1% to 1%): Atrial flutter

Frequency not reported: Increased heart rate

Hepatic

Common (1% to 10%): Increased ALT, gamma glutamyltransferase

Immunologic

In a pooled trials, 116 (5.5%) of 2,098 patients exposed to this drug tested positive for anti-albiglutide (the active ingredient contained in Tanzeum) antibodies at any time during the trials. None of these antibodies were shown to neutralize the activity of albiglutide in an in vitro bioassay.

Very common (10% or more): Positive test for anti-albiglutide antibodies

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Tanzeum